Skip to main content
Top
Published in: Journal of Ovarian Research 1/2018

Open Access 01-12-2018 | Research

Comparison of benign peritoneal fluid- and ovarian cancer ascites-derived extracellular vesicle RNA biomarkers

Authors: Cindy M. Yamamoto, Melanie L. Oakes, Taku Murakami, Michael G. Muto, Ross S. Berkowitz, Shu-Wing Ng

Published in: Journal of Ovarian Research | Issue 1/2018

Login to get access

Abstract

Background

Extracellular vesicles (EVs) are considered as a new class of resources for potential biomarkers. We analyzed expression of specific mRNA and miRNA in EVs derived from ovarian cancer ascites and the ideal controls, peritoneal fluids from benign patients for potential early detection and prognostic biomarkers.

Methods

Fluids were collected from subjects with benign cysts or endometrioma (n = 10), or low/high grade serous ovarian carcinoma (n = 8). EV particles were captured using primarily ExoComplete filterplate or ultracentrifugation and analyzed by nanoparticle tracking analysis, ELISA, and scanning electron microscopy. EV RNAs extracted from two ascites and three peritoneal fluids were submitted for next-generation sequencing. The expression of 34 mRNA and 18 miRNAs in the EVs isolated from patient fluids and cell line media was determined using qPCR.

Results

EVs isolated from patient samples had concentrations greater than 1010 EV particles/mL and 30% were EpCAM-positive based on ELISA. EV particle sizes averaged 113 ± 11.5 nm. The qPCR studies identified five mRNA (CA11, MEDAG, LAMA4, SPINT2, NANOG) and six miRNA (let-7b, miR23b, miR29a, miR30d, miR205, miR720) that were significantly differentially expressed between cancer ascites and peritoneal fluids. In addition, CA11 mRNA was decreased to 0.5-fold and SPINT2 and NANOG mRNA were significantly increased up to 100-fold in conditioned media of cancer cells compared to immortalized ovarian surface and fallopian tube epithelial cell lines, the hypothesized cells of origin for ovarian cancer development.

Conclusions

This study indicates that EV mRNA profiles can reflect the disease stage and may provide a potentially novel source for discovery of biomarkers in ovarian cancer.
Appendix
Available only for authorised users
Literature
3.
go back to reference Skates SJ, Xu FJ, Yu YH, Sjovall K, Einhorn N, Chang Y, et al. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer. 1995;76(Suppl 10):2004–10.CrossRefPubMed Skates SJ, Xu FJ, Yu YH, Sjovall K, Einhorn N, Chang Y, et al. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer. 1995;76(Suppl 10):2004–10.CrossRefPubMed
4.
go back to reference Streppel MM, Vincent A, Mukherjee R, Campbell NR, Chen SH, Konstantopoulos K, et al. Mucin 16 (cancer antigen 125 ) expression in human tissues and cell lines and correlation with clinical outcome in adenocarcinomas of the pancreas, esophagus, stomach, and colon. Hum Pathol. 2012;43:10.CrossRef Streppel MM, Vincent A, Mukherjee R, Campbell NR, Chen SH, Konstantopoulos K, et al. Mucin 16 (cancer antigen 125 ) expression in human tissues and cell lines and correlation with clinical outcome in adenocarcinomas of the pancreas, esophagus, stomach, and colon. Hum Pathol. 2012;43:10.CrossRef
5.
go back to reference Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin. 2011;61:3.CrossRef Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin. 2011;61:3.CrossRef
6.
go back to reference Buys SS, Partridge E, Black A, et al. Effect of screening on ovarian cancer mortality: the prostate, lung, colorectal and ovarian (PLCO) cancer screening randomized controlled trial. JAMA. 2011;305:22.CrossRef Buys SS, Partridge E, Black A, et al. Effect of screening on ovarian cancer mortality: the prostate, lung, colorectal and ovarian (PLCO) cancer screening randomized controlled trial. JAMA. 2011;305:22.CrossRef
7.
go back to reference Dorayappan KDP, Wallbillich JJ, Cohn DE, Selvendiran K. The biological significance and clinical applications of exosomes in ovarian cancer. Gynecol Oncol. 2016;142:1.CrossRef Dorayappan KDP, Wallbillich JJ, Cohn DE, Selvendiran K. The biological significance and clinical applications of exosomes in ovarian cancer. Gynecol Oncol. 2016;142:1.CrossRef
9.
go back to reference Nakamura K, Sawada K, Kinose Y, Yoshimura A, Toda A, Nakatsuka E, et al. Exosomes promote ovarian cancer cell invasion through transfer of CD44 to peritoneal mesothelial cells. Mol Cancer Res. 2017;15:1.CrossRef Nakamura K, Sawada K, Kinose Y, Yoshimura A, Toda A, Nakatsuka E, et al. Exosomes promote ovarian cancer cell invasion through transfer of CD44 to peritoneal mesothelial cells. Mol Cancer Res. 2017;15:1.CrossRef
10.
go back to reference Zhou J, Gong G, Tan H, Dai F, Zhu X, Chen Y, et al. Urinary microRNA-30a-5p is a potential biomarker for ovarian serous adenocarcinoma. Onc Rep. 2015;33:6. Zhou J, Gong G, Tan H, Dai F, Zhu X, Chen Y, et al. Urinary microRNA-30a-5p is a potential biomarker for ovarian serous adenocarcinoma. Onc Rep. 2015;33:6.
11.
go back to reference Im H, Shao H, Park YI, Peterson VM, Castro CM, Weissleder R, et al. Label-free detection and molecular profiling of exosomes with a nano-plasmonic sensor. Nat Biotechnol. 2014;32:5.CrossRef Im H, Shao H, Park YI, Peterson VM, Castro CM, Weissleder R, et al. Label-free detection and molecular profiling of exosomes with a nano-plasmonic sensor. Nat Biotechnol. 2014;32:5.CrossRef
12.
go back to reference Karst AM, Levanon K, Drapkin R. Modeling high-grade serous ovarian carcinogenesis from the fallopian tube. PNAS. 2011;108:18.CrossRef Karst AM, Levanon K, Drapkin R. Modeling high-grade serous ovarian carcinogenesis from the fallopian tube. PNAS. 2011;108:18.CrossRef
13.
go back to reference Zhang Y, Kwok JS-L, Choi P-W, Liu M, Yang J, Singh M, et al. Pinin interacts with C-terminal binding proteins for RNA alternative splicing and epithelial cell identity of human ovarian cancer cells. Oncotarget. 2016;7:10. Zhang Y, Kwok JS-L, Choi P-W, Liu M, Yang J, Singh M, et al. Pinin interacts with C-terminal binding proteins for RNA alternative splicing and epithelial cell identity of human ovarian cancer cells. Oncotarget. 2016;7:10.
14.
go back to reference Yan J, Jiang J-Y, Meng X-N, Xiu Y-L, Zong Z-H. MiR-23b targets cyclin G1 and suppresses ovarian cancer tumorigenesis and progression. J Exp Clin Ca Res. 2016;35:31.CrossRef Yan J, Jiang J-Y, Meng X-N, Xiu Y-L, Zong Z-H. MiR-23b targets cyclin G1 and suppresses ovarian cancer tumorigenesis and progression. J Exp Clin Ca Res. 2016;35:31.CrossRef
15.
go back to reference Li J, Hu K, Gong G, Zhu D, Wang Y, Liu H, et al. Upregulation of miR-205 transcriptionally suppresses SMAD4 and PTEN and contributes to human ovarian cancer progression. Sci Reports. 2016;1:7. Li J, Hu K, Gong G, Zhu D, Wang Y, Liu H, et al. Upregulation of miR-205 transcriptionally suppresses SMAD4 and PTEN and contributes to human ovarian cancer progression. Sci Reports. 2016;1:7.
16.
go back to reference Meng X, Muller V, Milde-Langosch K, Trillsch F, Pantel K, Schwrzenbach H. Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer. Oncotarget. 2016;7:13. Meng X, Muller V, Milde-Langosch K, Trillsch F, Pantel K, Schwrzenbach H. Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer. Oncotarget. 2016;7:13.
17.
go back to reference Yeung CLA, Co N-N, Tsuruga T, Yeung T-L, Kwan S-Y, Leung CS, et al. Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1. Nat Commun. 2016;29:7. Yeung CLA, Co N-N, Tsuruga T, Yeung T-L, Kwan S-Y, Leung CS, et al. Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1. Nat Commun. 2016;29:7.
18.
go back to reference Wu RL, Ali S, Bandyopadhyay S, Alosh B, Hayek K, Daaboul MHD, et al. Comparative analysis of differentially expressed miRNAs and their downstream mRNAs in ovarian cancer and its associated endometriosis. J cancer Sci Ther. 2105;7:7. Wu RL, Ali S, Bandyopadhyay S, Alosh B, Hayek K, Daaboul MHD, et al. Comparative analysis of differentially expressed miRNAs and their downstream mRNAs in ovarian cancer and its associated endometriosis. J cancer Sci Ther. 2105;7:7.
19.
go back to reference Kipps E, DSP T, Kaye SB. Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Ca. 2103;13:4. Kipps E, DSP T, Kaye SB. Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Ca. 2103;13:4.
20.
go back to reference O DF, Roskams T, Van den Eynde K, Vanhie A, Peterse DP, et al. The presence of endometrial cells in peritoneal fluid of women with and without endometriosis. Reprod Sci. 2017;24:2. O DF, Roskams T, Van den Eynde K, Vanhie A, Peterse DP, et al. The presence of endometrial cells in peritoneal fluid of women with and without endometriosis. Reprod Sci. 2017;24:2.
21.
go back to reference Perets R, Wyant GA, Muto KW, Bijron JG, Poole BB, et al. Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell. 2013;24:6.CrossRef Perets R, Wyant GA, Muto KW, Bijron JG, Poole BB, et al. Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell. 2013;24:6.CrossRef
22.
go back to reference Yoshikawa Y, Mukai H, Hino F, Asada K, Kato I. Isolation of two novel genes, down-regulated in gastric cancer. Jpn J Cancer Res. 2000;91:5.CrossRef Yoshikawa Y, Mukai H, Hino F, Asada K, Kato I. Isolation of two novel genes, down-regulated in gastric cancer. Jpn J Cancer Res. 2000;91:5.CrossRef
23.
go back to reference Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med. 2011;17:11.CrossRef Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med. 2011;17:11.CrossRef
24.
go back to reference Yeung TL, Leung CS, Wong KK, Samimi G, Thompson MS, Liu J, et al. TGF-b modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment. Ca Research. 2013;73:16.CrossRef Yeung TL, Leung CS, Wong KK, Samimi G, Thompson MS, Liu J, et al. TGF-b modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment. Ca Research. 2013;73:16.CrossRef
26.
go back to reference Muller-Pillasch F, Wallrapp C, Bartels K, Varga G, Friess H, Buchler M, et al. Cloning of a new Kunitz-type protease inhibitor with a putative transmembrane domain overexpressed in pancreatic cancer. Biochim Biophys Acta. 1998;1395:1.CrossRef Muller-Pillasch F, Wallrapp C, Bartels K, Varga G, Friess H, Buchler M, et al. Cloning of a new Kunitz-type protease inhibitor with a putative transmembrane domain overexpressed in pancreatic cancer. Biochim Biophys Acta. 1998;1395:1.CrossRef
27.
go back to reference Pan Y, Jiao J, Zhou C, Cheng Q, Hu Y, Chen H. Nanog is highly expressed in ovarian serous cystadenocarcinoma and correlated with clinical stage and pathological grade. Pathobiology. 2011;77:6. Pan Y, Jiao J, Zhou C, Cheng Q, Hu Y, Chen H. Nanog is highly expressed in ovarian serous cystadenocarcinoma and correlated with clinical stage and pathological grade. Pathobiology. 2011;77:6.
28.
go back to reference Kenda Suster N, Frkovic Grazio S, Virant-Klun I, Verdenik I, Smrkolj S. Cancer stem cell-related marker NANOG expression in ovarian serous tumors: a clinicopathological study of 159 cases. Int J Gynecol Cancer. 2017;9:2006.CrossRef Kenda Suster N, Frkovic Grazio S, Virant-Klun I, Verdenik I, Smrkolj S. Cancer stem cell-related marker NANOG expression in ovarian serous tumors: a clinicopathological study of 159 cases. Int J Gynecol Cancer. 2017;9:2006.CrossRef
29.
go back to reference Zaman MS, Maher DM, Khan S, Jaggi M, Chauhan SC. Current status and implications of microRNAs in ovarian cancer diagnosis and therapy. J Ovarian Research. 2012;5:44.CrossRef Zaman MS, Maher DM, Khan S, Jaggi M, Chauhan SC. Current status and implications of microRNAs in ovarian cancer diagnosis and therapy. J Ovarian Research. 2012;5:44.CrossRef
Metadata
Title
Comparison of benign peritoneal fluid- and ovarian cancer ascites-derived extracellular vesicle RNA biomarkers
Authors
Cindy M. Yamamoto
Melanie L. Oakes
Taku Murakami
Michael G. Muto
Ross S. Berkowitz
Shu-Wing Ng
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Journal of Ovarian Research / Issue 1/2018
Electronic ISSN: 1757-2215
DOI
https://doi.org/10.1186/s13048-018-0391-2

Other articles of this Issue 1/2018

Journal of Ovarian Research 1/2018 Go to the issue